Literature DB >> 3393000

The characteristics of thymoma with myasthenia gravis: a 28-year experience.

Y Monden1, T Uyama, T Taniki, J Hashimoto, Y Fujii, K Nakahara, Y Kawashima, A Masaoka.   

Abstract

Of 134 patients with thymoma, 79 (59%) also had myasthenia gravis (MG). The thymoma with MG differed from that in the absence of MG in the following aspects: The ratio of lymphocytes to epithelial cells in the tumor was larger, the polygonal cell type was more prominent (i.e., in 83% of the MG patients this cell type predominated), and the differentiation of epithelial cells in the tumor was more advanced in the group with MG than in the group without MG. Furthermore, the clinical stage of thymoma was earlier, the recurrence rate was lower, and the survival curve was better in the group with MG than in the group without MG. These findings suggest that the thymoma with MG is less malignant than that without MG.

Entities:  

Mesh:

Year:  1988        PMID: 3393000     DOI: 10.1002/jso.2930380305

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  4 in total

1.  A case of encapsulated noninvasive thymoma (stage I) with myasthenia gravis showing metastasis after a 2-year dormancy.

Authors:  A Masunaga; I Sugawara; T Yoshitake; H Nakamura; S Itoyama; N Shimoyama; T Ishidate
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

2.  Results from surgical treatment for thymoma. 43 years of experience.

Authors:  T Murakawa; J Nakajima; T Kohno; M Tanaka; J Matsumoto; E Takeuchi; S Takamoto
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2000-02

3.  A population-based assessment of mortality and morbidity patterns among patients with thymoma.

Authors:  Shahinaz M Gadalla; Arun Rajan; Ruth Pfeiffer; Sigurdur Y Kristinsson; Magnus Björkholm; Ola Landgren; Giuseppe Giaccone
Journal:  Int J Cancer       Date:  2010-07-28       Impact factor: 7.396

4.  Prognostic factors of patients with thymoma.

Authors:  W S Lee; D S Heo; Y J Bang; K S Lee; J S Ahn; C W Jung; S K Han; S W Sung; J H Kim; Y S Shim; C I Park; N K Kim
Journal:  Korean J Intern Med       Date:  1996-01       Impact factor: 2.884

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.